Alirocumab, identified by 1245916-14-6, signifies a recently developed monoclonal immunoglobulin specifically to target proprotein convertase subtilisin-kexin type 9 – a key regulator of "bad" cholesterol https://www.targetmol.com/compound/alirocumab
Alirocumab (1245916-14-6): A Deep Dive
Internet - 4 hours ago wcd118084573Web Directory Categories
Web Directory Search
New Site Listings